Search

PxWire Volume 15, Issue 3

This issue of PxWire looks at the scale of shuttered prevention programs for key populations, the potential market for injectable LEN, and the devastating cuts to research for an HIV vaccine.

Protecting Your Health

Impact of US Funding Cuts on Services for Key Populations

Percentage of key population-serving implementing partners that have reported full or partial termination of the provision of KP services due to US funding cuts (as of April 2025).

Impact of Cuts to the Consortia for HIV/AIDS Vaccine Development (CHAVD)

In May 2025, NIH’s National Institute of Allergy and Infectious Diseases (NIAID) announced that funding for the Consortia for HIV/AIDS Vaccine Development (CHAVD) would end after the current grant cycle in June 2026. With only one more year of funding before the grants end, current plans for research, clinical trials and progress toward a vaccine are all at risk.

Potential Demand for LEN for PrEP

The top 16 PrEP markets, based on 2024 oral PrEP initiations and the possible 2026 injectable market, assuming 60% of new PrEP users choose an injectable, as seen in implementation studies.

Supreme Court Upholds ACA Preventive-Care Protections

AVAC welcomes today’s ruling affirming the constitutionality of the Affordable Care Act’s preventive services mandate, including coverage for HIV pre-exposure prophylaxis (PrEP) at no cost to patients. This decision represents a critical victory for public health, health equity, and the millions of people who rely on preventive services to stay healthy and safe.

Important Win for Public Health: Supreme Court Upholds ACA Preventive-Care Protections 

AVAC welcomes today’s ruling affirming the constitutionality of the Affordable Care Act’s preventive services mandate, including coverage for PrEP at no cost to patients. This decision represents a critical victory for public health, health equity, and the millions of people who rely on preventive services to stay healthy and safe.

Global Health Watch: USAID in the Spotlight, Gavi Replenishment, Defense of the Rescissions Package and ACIP

This week brought major media attention to the devastating dismantling of USAID, even as the FDA’s approval of lenacapavir for PrEP signaled new hope in HIV prevention. At the same time, vaccines were under even greater assault as the US administration announced it would withdraw support from Gavi based on spurious claims, while the CDC’s Advisory Committee on Immunization Practices met for the first time since the Secretary of Health and Human Services fired leading vaccine experts and replaced them with a group of skeptics.

The Cruel Irony of Prevention

It’s only been 22 weeks since the US President began dismantling US foreign aid. AVAC took a public stand against this attack on global health in our court case. All this comes at the same time as the introduction of a potentially transformational moment in HIV prevention — the introduction of injectable lenacapavir for PrEP.

IAS 2025